Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection

摘要: Summary Objectives Maraviroc currently represents an important antiretroviral drug for multi-experienced and viremic HIV patients. This study focused on two main points: (1) determining the prevalence of R5 X4 strains in antiretroviral-experienced patients using tests use to determine viral tropism, (2) follow-up 3 years a limited number who started new protocol including maraviroc. Methods A group 56 patients, previously multi-treated, were first analyzed by genotyping assay Trofile™ establish their eligibility maraviroc treatment. In addition, 25 subjects selected follow therapeutic CCR5 antagonist monitored RNA load CD4+ cell count. Results The determination tropism showed large percentage with profile (72% 74% Trofile). most (21 out 25) undetectable throughout observation period, accompanied major improvement CD4 count (cells/mm ) (baseline: median 365, interquartile range (IQR) 204–511; 12 months: value 501, IQR 349–677, p =0.042; 24 503, 386–678, =0.026; 36 601, 517–717, =0.001). Among four non-responder subjects, lack compliance switched from X4. Conclusion Although our patient cohort was small, results high As well as showing advantages genotyping, which can be performed plasma samples low replication, alternative protocol, antagonist, persistent replication good recovery treated